Overview

A Study of SGN-CD228A in Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SGN-CD228A should be given for treatment and how often. Part 2 of the study will use the dose found in Part 1 and look at how safe and effective the treatment is.
Phase:
Phase 1
Details
Lead Sponsor:
Seagen Inc.
Seattle Genetics, Inc.